Combination of anlotinib and Tislelizumab for lung adenocarcinoma: effects on metabolic and flora microenvironment and exploration of prognosis-related biomarkers
To investigate the specific mechanism of action of the immune checkpoint inhibitor tislelizumab in combination with anlotinib in the treatment of lung adenocarcinoma from the perspectives of immune cells, cytokines, intestinal flora, metabolomics, etc., so as to provide a basis for better individualized and comprehensive treatment.